Department of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA.
Int J Clin Oncol. 2009 Oct;14(5):478-81. doi: 10.1007/s10147-008-0873-0. Epub 2009 Oct 25.
Pancreatic adenocarcinoma is the fourth leading cause of cancer deaths in the United States. Current 5-year survival is less than 4%, highlighting the dire need for effective treatment. We report the case of a 41-year-old woman who was diagnosed with advanced metastatic well-to-moderately differentiated mucinous adenocarcinoma of the pancreas, involving the liver and peritoneal cavity. She agreed to receive novel combination chemotherapy rather than the standard-of-care treatment. This patient was treated with three unique combination regimens. Complete response of multiple liver and peritoneal metastases and reduction in size with increasing calcification of the pancreatic mass occurred in this patient after 18 months of treatment. This report documents the individual response to effective and well-tolerated treatment regimens integrating available drugs.
胰腺腺癌是美国癌症死亡的第四大主要原因。目前的 5 年生存率不足 4%，这突显了对有效治疗方法的迫切需求。我们报告了一例 41 岁女性的病例，她被诊断患有晚期转移性中高度分化黏液性腺癌，累及肝脏和腹腔。她同意接受新型联合化疗，而不是标准治疗。该患者接受了三种独特的联合治疗方案。在治疗 18 个月后，该患者的多个肝和腹膜转移灶完全缓解，胰腺肿块的大小缩小，并且出现了越来越多的钙化。本报告记录了个体对有效且耐受良好的治疗方案的反应，这些方案整合了现有药物。
